ANDA 214971, held by Be Pharms. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 214971 (Sodium Nitroprusside), held by Be Pharms, was first approved by FDA on Jul 12, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 12, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML · injectable;injection | Sodium Nitroprusside | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters